Congestive heart failure is a condition in which the heart is unable to pump enough blood to the rest of the body. It is a long-term, chronic illness that usually affects both sides of the heart, although it is possible for just the right or left side to be affected.
As the heart is unable to pump oxygen rich blood around the body, blood can accumulate in various areas, causing a build-up of fluid in the arms, legs, lungs, liver, and gastrointestinal tract. Organs do not receive enough oxygen or nutrition and become damaged and poorly functioning.
The most common cause of congestive heart failure is coronary artery disease, a condition in which the small blood vessels that supply the heart with blood and oxygen become narrowed.
Congestive heart failure symptoms can come on quite gradually. The most common ones are a cough, shortness of breath, weight gain, swelling of feet, ankles and abdomen, palpitations, insomnia, rapid or irregular pulse, loss of appetite and fatigue.
Stem Cells for Congestive Heart Failure
Adult stem cells, which are undifferentiated, can mutate into the cells of many different organs and structures within the human body. They can be used in many different therapies and are very effective at restoring damaged fibers and renewing failing cells. This work is carried out through cell division, a process in which stem cells multiply indefinitely. Stem cell application science has improved vastly in the last few years with many new developments and discoveries being made.
Stem Cell Application at Angeles Hospital
Angeles hospital has created the Adult Autologous Stem Cell (A-ASC) Therapy program to treat congestive heart failure as well as countless other medical conditions. In the case of congestive heart failure autologous adult stem cells are used, which means they come from the patient’s own body. The possibility of a patient rejecting the cells is therefore little to none.
Stem cells used are extracted from the patient’s bone marrow and adipose tissue, or fat. Adipose tissue extraction is easier than bone marrow extraction as the tissue contains up to ten times more stem cells. Bone marrow extraction is also more of an arduous task to carry out.
The Stem Cell Application program at Hospital Angeles uses this targeted therapeutic endovascular placement of adipose-derived adult autologous stem cells to come as close as possible to the organ or structure to be treated.
The non-invasive catheterization procedure is easy for the patient and stem cells can be distributed throughout the body. Anesthesia is unnecessary and the process is completed in under an hour.
This Center of Excellence offers congestive heart failure patients up to date therapies that are of the highest quality. Doctors promote and define best practices through evaluating results, collaborative learning and establishing protocols. Angeles Health International practices with multi-disciplinary groups of licensed health care providers who adhere to formally appointed bodies of expertise. This ensures the highest standards for therapy as well as investigative research are upheld.
Inclusion/Exclusion Criteria for Therapy
Eligible patients must meet ALL of the following inclusion criteria during the screening/enrollment visit #1.
- Willing and able to sign informed consent
- Age >18 years and < 80 years
- NYHA Class II-IV
- Ischemic cardiomyopathy without an acute coronary syndrome during the prior 6 months
- LVEF less than or equal to 35% measured by echocardiography at both local and investigative sites, AND:
- Well-demarcated region of LV systolic dysfunction.
- Left ventricular wall without mural thrombus and of thickness greater than 0.5 cm
- No significant valvular disease including: Moderate-to-severe mitral regurgitation (3-4+), aortic stenosis (valve area <1.5 cm2), aortic insufficiency (3-4+)
At the time of the screening/enrollment visit #1, patients meeting ANY ONE of the following criteria will be excluded from the study.
- Non-ischemic myocardial disease
- Limiting symptoms due to non-CHF causes, such as lung disease, peripheral vascular disease, arthritis or other musculoskeletal disorders
- Inability to complete a 6-minute walk test for any reason
- Need for intravenous CHF medications, chronic continuous oxygen therapy or oral steroids,
- CABG surgery within 150 days prior to screening
- Planned revascularization within 4 months following enrollment
- Aortic aneurysm or dilatation (>3.8 cm by echocardiography or other imaging modality)
- Peripheral vascular disease at or below the distal aorta that may interfere with MyoCath® use
- Hemodynamically significant pericardial disease
- Prior aortic or mitral valve replacement
- Biventricular pacing device implant within the last 3 months OR whose device is scheduled to be revised following enrollment in this trial
- Expected to receive or history of cardiac transplant, surgical remodeling procedure, left ventricular assist device
- Stroke or transient ischemic attack within 180 days of screening
- Positive pregnancy test in women of child bearing potential or who are unwilling to use an acceptable method of contraception.
- Drug or alcohol dependence
- Life expectancy of less than 1 year
- History of cancer (other than non-melanoma skin cancer or in situ cervical cancer) in the last five years
- Exposure to angiogenic therapy (including myocardial laser) or another investigational drug within 60 days of screening, or enrollment in any concurrent study that may confound the results of this study
- Any factors in the opinion of the Investigator which render the patient unsuitable for participation, that will interfere with conduct of the study or interpretation of the results.
More on Stem Cell Application!
If you would like to learn more about the Stem Cell Application options at Angeles hospital in Mexico please contact us using the form on your right.